Acurx Pharmaceuticals (ACXP) vs Skye Bioscience (SKYE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Skye Bioscience is the larger company by market cap ($7.6 million vs $7.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACXP | SKYE |
|---|---|---|
| Share price | $1.27 | $1.72 |
| Market cap | $7.06M | $7.62M |
| 1-day change | +1.62% | +2.37% |
| EPS (TTM) | $-2.67 | $-10.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.98 | $14.08 |
| 52-week low | $1.23 | $1.50 |
| Distance from 52-week high | -84.09% | -87.78% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +1238.69% | +3853.49% |
| Average volume | 125.08K | 89.28K |
| Shares outstanding | 5.56M | 4.43M |
| Employees | 4 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Acurx Pharmaceuticals
ACXP stock →Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Skye Bioscience
SKYE stock →Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
ACXP vs SKYE FAQ
Which is bigger, Acurx Pharmaceuticals or Skye Bioscience?
Skye Bioscience (SKYE) is larger, with a market capitalization of $7.62M compared with $7.06M for Acurx Pharmaceuticals (ACXP).
Are Acurx Pharmaceuticals and Skye Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.